Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.

C/EBPβ MYB cancer celastrol leukemia naphthoquinone natural product p300 plumbagin sesquiterpene lactone transcription factor withaferin A withanolide

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
23 Mar 2022
Historique:
received: 02 03 2022
revised: 21 03 2022
accepted: 22 03 2022
entrez: 12 4 2022
pubmed: 13 4 2022
medline: 14 4 2022
Statut: epublish

Résumé

The transcription factor MYB is expressed predominantly in hematopoietic progenitor cells, where it plays an essential role in the development of most lineages of the hematopoietic system. In the myeloid lineage, MYB is known to cooperate with members of the CCAAT box/enhancer binding protein (C/EBP) family of transcription factors. MYB and C/EBPs interact with the co-activator p300 or its paralog CREB-binding protein (CBP), to form a transcriptional module involved in myeloid-specific gene expression. Recent work has demonstrated that MYB is involved in the development of human leukemia, especially in acute T-cell leukemia (T-ALL) and acute myeloid leukemia (AML). Chemical entities that inhibit the transcriptional activity of the MYB-C/EBPβ-p300 transcription module may therefore be of use as potential anti-tumour drugs. In searching for small molecule inhibitors, studies from our group over the last 10 years have identified natural products belonging to different structural classes, including various sesquiterpene lactones, a steroid lactone, quinone methide triterpenes and naphthoquinones that interfere with the activity of this transcriptional module in different ways. This review gives a comprehensive overview on the various classes of inhibitors and the inhibitory mechanisms by which they affect the MYB-C/EBPβ-p300 transcriptional module as a potential anti-tumor target. We also focus on the current knowledge on structure-activity relationships underlying these biological effects and on the potential of these compounds for further development.

Identifiants

pubmed: 35408476
pii: molecules27072077
doi: 10.3390/molecules27072077
pmc: PMC9000602
pii:
doi:

Substances chimiques

Biological Products 0
CCAAT-Enhancer-Binding Proteins 0
Transcription Factors 0
Triterpenes 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Mol Cell Biol. 1996 Apr;16(4):1316-25
pubmed: 8657104
Mol Cell Biol. 2008 Mar;28(6):2102-12
pubmed: 18195047
Oncogene. 2021 Jul;40(29):4746-4758
pubmed: 33958723
Blood. 2014 Apr 24;123(17):2682-90
pubmed: 24596419
Trends Cell Biol. 2007 Jul;17(7):318-24
pubmed: 17658261
Blood. 2006 Jul 1;108(1):297-304
pubmed: 16507773
EMBO J. 2010 Mar 17;29(6):1105-15
pubmed: 20111005
PLoS One. 2018 Feb 2;13(2):e0190934
pubmed: 29394256
Nat Immunol. 2004 Jul;5(7):721-9
pubmed: 15195090
Curr Pharm Des. 2018;24(36):4355-4361
pubmed: 30659534
Blood. 2007 Aug 15;110(4):1251-61
pubmed: 17452517
J Mol Med (Berl). 2016 Dec;94(12):1385-1395
pubmed: 27522676
Mol Cell Biol. 1997 Nov;17(11):6609-17
pubmed: 9343424
Leukemia. 2012 Apr;26(4):615-22
pubmed: 21986841
Nat Genet. 2007 May;39(5):593-5
pubmed: 17435759
EMBO J. 1996 Jun 3;15(11):2771-80
pubmed: 8654374
Curr Drug Targets. 2011 Oct;12(11):1560-73
pubmed: 21561425
J Nat Prod. 2020 Mar 27;83(3):770-803
pubmed: 32162523
Cell. 1989 Dec 22;59(6):1115-25
pubmed: 2688896
Exp Hematol. 2022 Apr;108:8-15
pubmed: 35032593
Int J Cancer. 2000 May 1;86(3):337-43
pubmed: 10760820
Eur J Med Chem. 2013 May;63:313-20
pubmed: 23501116
Prostate. 2009 Sep 15;69(13):1435-47
pubmed: 19489038
Nat Genet. 2013 Jun;45(6):602-12
pubmed: 23583981
Oncogenesis. 2021 Feb 26;10(2):19
pubmed: 33637673
Nature. 2010 Jan 21;463(7279):318-25
pubmed: 20032975
Cell Cycle. 2006 May;5(9):953-7
pubmed: 16687924
Blood. 2017 Jun 15;129(24):3221-3226
pubmed: 28270453
Leukemia. 2016 Jul;30(7):1612-5
pubmed: 26854027
Chem Res Toxicol. 2012 Feb 20;25(2):239-51
pubmed: 22053936
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3829-34
pubmed: 17360438
Mol Cell. 2015 Jun 18;58(6):1028-39
pubmed: 25982114
J Exp Med. 2007 Dec 24;204(13):3059-66
pubmed: 18070937
Nat Rev Cancer. 2008 Jul;8(7):523-34
pubmed: 18574464
Cell. 1982 Dec;31(2 Pt 1):453-63
pubmed: 6297766
Biochim Biophys Acta Mol Cell Res. 2017 Jul;1864(7):1349-1358
pubmed: 28476645
J Biol Chem. 2001 Oct 26;276(43):39713-20
pubmed: 11500489
Oncogene. 1995 Dec 7;11(11):2273-9
pubmed: 8570177
J Biol Chem. 2016 Dec 9;291(50):26098-26108
pubmed: 27803164
Immunity. 2005 Sep;23(3):275-86
pubmed: 16169500
Bioorg Med Chem. 1997 Apr;5(4):645-53
pubmed: 9158862
Curr Med Chem. 2018;25(15):1704-1719
pubmed: 29189124
J Biol Chem. 1998 Dec 11;273(50):33508-16
pubmed: 9837931
Int J Clin Exp Pathol. 2015 Dec 01;8(12):15652-60
pubmed: 26884834
Oncogene. 2003 Jan 16;22(2):308-13
pubmed: 12527900
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6553-8
pubmed: 15071178
Nat Prod Rep. 2022 Apr 20;39(4):784-813
pubmed: 34816854
Cell Signal. 2012 Jun;24(6):1287-96
pubmed: 22374303
Cell. 1991 Nov 1;67(3):569-79
pubmed: 1934061
Mol Cell Biol. 2005 Jan;25(1):499-511
pubmed: 15601869
Curr Drug Targets. 2019;20(4):444-452
pubmed: 30317996
J Biol Chem. 2003 Aug 29;278(35):33416-21
pubmed: 12810706
Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13762-7
pubmed: 17690249
Cell Stem Cell. 2009 Feb 6;4(2):129-40
pubmed: 19200802
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18740-4
pubmed: 19841262
Acta Crystallogr D Biol Crystallogr. 2014 Jul;70(Pt 7):1914-21
pubmed: 25004968
J Biol Chem. 2004 Feb 20;279(8):6658-65
pubmed: 14966110
EMBO J. 2003 Sep 1;22(17):4478-88
pubmed: 12941699
Genes Dev. 1993 May;7(5):749-59
pubmed: 7684005
Chem Biol Drug Des. 2018 Mar;91(3):681-690
pubmed: 29130595
Oncol Rep. 2006 Mar;15(3):595-601
pubmed: 16465418
Bioorg Med Chem. 1999 Nov;7(11):2343-52
pubmed: 10632044
J Clin Invest. 2006 Dec;116(12):3171-82
pubmed: 17111047
J Immunol. 1995 Dec 1;155(11):5273-9
pubmed: 7594540
Dev Cell. 2005 Feb;8(2):153-66
pubmed: 15691758
Am J Pathol. 2001 Apr;158(4):1289-99
pubmed: 11290547
Genes Dev. 1994 Nov 15;8(22):2781-91
pubmed: 7958933
Nat Prod Rep. 2011 Apr;28(4):705-40
pubmed: 21344104
Nucleic Acids Res. 2011 Jun;39(11):4664-79
pubmed: 21317192
Bioorg Med Chem. 1999 Dec;7(12):2849-55
pubmed: 10658589
J Med Chem. 2014 Oct 9;57(19):7874-87
pubmed: 24946140
iScience. 2019 Mar 29;13:351-370
pubmed: 30884312
Oncogene. 2006 Feb 2;25(5):795-805
pubmed: 16205643
J Biol Chem. 2013 Aug 2;288(31):22257-69
pubmed: 23782693
Genes Dev. 1996 Mar 1;10(5):528-40
pubmed: 8598284
Mol Cell. 1999 Nov;4(5):735-43
pubmed: 10619021
Curr Opin Cell Biol. 2008 Apr;20(2):180-5
pubmed: 18358708
J Immunol. 1999 Sep 1;163(5):2674-80
pubmed: 10453008
Mol Cancer Ther. 2016 Dec;15(12):2905-2915
pubmed: 27707899
EMBO J. 1993 May;12(5):2027-38
pubmed: 8491193
Cell. 1991 May 17;65(4):677-89
pubmed: 1709592
Nat Genet. 2016 Mar;48(3):273-82
pubmed: 26829751
Mol Cell Biol. 2000 Feb;20(3):912-8
pubmed: 10629048
Mol Cell. 1999 Dec;4(6):1087-92
pubmed: 10635333
Bioorg Med Chem. 2020 Apr 1;28(7):115357
pubmed: 32081630
J Biol Chem. 2008 Sep 26;283(39):26357-63
pubmed: 18647749
Blood. 1992 Jan 15;79(2):460-6
pubmed: 1730090
Genes Dev. 2000 Aug 1;14(15):1920-32
pubmed: 10921906
Genes Dev. 2011 Aug 1;25(15):1628-40
pubmed: 21828272
Nat Genet. 2016 Mar;48(3):265-72
pubmed: 26829750
Cancer Lett. 2022 Apr 1;530:170-180
pubmed: 35077804
J Biol Chem. 2009 Sep 4;284(36):24453-64
pubmed: 19570987
Genes Chromosomes Cancer. 2006 Dec;45(12):1143-54
pubmed: 16977606
Nature. 2002 Oct 17;419(6908):738-43
pubmed: 12384703
Haematologica. 2010 May;95(5):760-7
pubmed: 20015877
Oncotarget. 2015 Feb 28;6(6):4369-84
pubmed: 25738360
Biochem Biophys Res Commun. 2010 Apr 9;394(3):439-42
pubmed: 20226165
Mol Cancer Res. 2009 Sep;7(9):1477-86
pubmed: 19737967
Blood. 2016 Mar 3;127(9):1173-82
pubmed: 26631113
Science. 2014 Dec 12;346(6215):1373-7
pubmed: 25394790
Mol Cell Endocrinol. 2008 Jul 16;289(1-2):94-101
pubmed: 18486321
J Mol Biol. 2004 Mar 26;337(3):521-34
pubmed: 15019774

Auteurs

Thomas J Schmidt (TJ)

Institute of Pharmaceutical Biology and Phytochemistry (IPBP), University of Münster, PharmaCampus-Corrensstraße 48, D-48149 Munster, Germany.

Karl-Heinz Klempnauer (KH)

Institute of Biochemistry, University of Münster, Corrensstraße 36, D-48149 Munster, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH